Skip to main content
Premium Trial:

Request an Annual Quote

Glaxo Buys Two More MassARRAYs From Sequenom

NEW YORK, Oct. 17 - Sequenom today said that GlaxoSmithKline likes its MassARRAY tools it bought earlier this year and has opened its wallet for two more units.

 

The sale also follows a collaboration between the two firms that helped Sequenom generate a "significant portion" of its SNP-assay portfolio, the company said.

 

Click here for more information.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.